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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the beneficial andharmful effects of endoscopic therapy andbeta-blockers used as a combination therapy versusmonotherapy
with either endoscopic therapy or beta-blockers for secondary prevention in people with cirrhosis and oesophageal varices.
B A C K G R O U N D
Description of the condition
People with cirrhosis develop oesophageal varices as a result of por-
tal hypertension (Bosch 2003; Triantos 2007). About 30% of peo-
ple with cirrhosis have oesophageal varices at the initial diagnosis
(D’Amico 1995; D’Amico 1999; D’Amico 2007; De Lisi 2011).
Five percent develop varices during the first year after the diagno-
sis, and 28% develop varices after three years (Merli 2003). The
estimated two-year incidence of bleeding is approximately 24%
(D’Amico 1995; D’Amico 1999), and 70% of these occur within
two years of diagnosis. The inhospital mortality associated with
variceal bleeding remains high. The overall risk ranges from 12%
to 44%, depending on the proportion of high-risk patients. The
risk of death within six weeks of the initial variceal haemorrhage is
less than 10% in Child-Pugh Class A and more than 32% in those
in Child-Pugh Class C (Carbonell 2004). The risk of rebleeding
after the first episode of an acute variceal haemorrhage is about
63% within the first two years after the diagnosis and mortality
is about 30% during the same period (D’Amico 1995; D’Amico
1999; D’Amico 2007).
Description of the intervention
Non-selective beta-blockers are recommended as secondary pre-
vention of variceal bleeding (Garcia-Tsao 2007; Tripathi 2007;
Garcia-Tsao 2008; Puente 2014). The drugs block the beta-1 and
-2 receptors, which are found in several tissues including vas-
cular smooth muscle and the heart. Beta-blockers used in clini-
cal practice are propranolol, nadolol, and timolol, and, in recent
years, carvedilol (Villanueva 2008). One meta-analysis with 20
randomised clinical trials found that beta-blockers reduced the
risk of rebleeding (Cheng 2003). However, about 30% of trial par-
ticipants did not respond to beta-blockers. The combination of
beta-blockers and endoscopic therapy may be more effective than
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beta-blockers alone (Gonzalez 2008; Shi 2013; Bai 2014; Puente
2014). The available endoscopic interventions include sclerother-
apy and banding ligation. Variceal sclerotherapy, which involves
injecting a strong and irritating sclerosant or glue, is associated
with severe bleeding and oesophageal strictures (Schmitz 2001).
Banding ligation may provide a safer option (Gluud 2007). Band-
ing devices use a means of capturing the target tissue while a small-
diameter circular band is deployed around the base of the tissue
(ASGE 2008). The band may be rubber, latex, or similar mate-
rials. The ligation procedure results in a tight compression with
vascular compromise leading to thrombosis, necrosis, and slough-
ing. Previous banding devices used an overtube for the repeated
intubation, allowing placement of multiple bands (Collins 2001).
The insertion of an overtube was associated with adverse events in-
cluding perforation of the oesophagus (Wong 2000; Gluud 2007).
Multi-band devices are now used, resulting in considerably fewer
adverse events (ASGE 2008).
How the intervention might work
Non-selective beta-blockers have beta-1 receptor effects and beta-
2 receptor effects. Beta-1 receptor blockade reduces cardiac out-
put and portal venous inflow. Beta-2 receptor blockade leads to
splanchnic vasoconstriction reducing the azygos blood flow and
variceal pressure (D’Amico 1999; D’Amico 2007). Banding liga-
tion works by capturing (ligating) a varix resulting in thrombosis.
The tissue then necroses and sloughs off after two to seven days.
The subsequent superficial mucosal ulceration heals within a few
days.
Why it is important to do this review
Previous meta-analyses have found a potential benefit of the com-
bination of beta-blockers and endoscopic therapy for preven-
tion of variceal rebleeding (Gonzalez 2008; Funakoshi 2010; Shi
2013; Bai 2014; Puente 2014). However, the effect on mortality
and risk of serious adverse events is unclear. The meta-analyses
evaluated different combinations of beta-blockers (alone or with
other drugs), banding ligation, and sclerotherapy. In addition, the
analyses included participants with or without cirrhosis. There-
fore, important differences may exist between subgroups and our
Cochrane Review will aim to clarify this.
O B J E C T I V E S
To evaluate the beneficial and harmful effects of endoscopic
therapy and beta-blockers used as a combination therapy versus
monotherapy with either endoscopic therapy or beta-blockers for
secondary prevention in people with cirrhosis and oesophageal
varices.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials irrespective of publication type, publi-
cation status, and language.
We have chosen to include randomised clinical trials because they
are more likely to provide unbiased information than other study
designs about the differential effects of alternative forms of health-
care. If, during the selection of trials, we identify observational
studies (i.e. quasi-randomised studies, cohort studies, or patient
reports) that report adverse events caused by, or associated with,
the interventions in our review, we will include these studies for
a review of the adverse events. We will not specifically search for
observational studies, which is a known limitation of our system-
atic review.
Types of participants
We will include adults (at least 18 years) with cirrhosis and endo-
scopically verified oesophageal varices that have bled.
Types of interventions
The intervention comparisons will include:
• banding ligation plus beta-blockers versus beta-blockers
alone;
• banding ligation plus beta-blockers versus banding ligation
alone;
• sclerotherapy plus beta-blockers versus beta-blockers alone;
• sclerotherapy plus beta-blockers versus sclerotherapy alone.
We will allow concurrent interventions such as isosorbide monon-
itrate or simvastatin to both intervention arms in our primary anal-
yses, and we will evaluate the effect of concomitant interventions
in subgroup analyses.
Types of outcome measures
We will assess all outcomes at the maximum duration of follow-
up in our primary analyses.
Primary outcomes
• Mortality (all-cause).
• Serious adverse events defined as any untoward medical
occurrence that does not necessarily have a causal relationship
with the treatment (ICH-GCP 1997). We will define serious
adverse events as those that led to death, were life-threatening, or
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required hospitalisation or prolongation of hospitalisation
(ICH-GCP 1997). We will analyse adverse events as a composite
outcome (Gluud 2017).
Secondary outcomes
• Bleeding-related mortality.
• Health-related quality of life.
• Upper gastrointestinal bleeding.
• Variceal bleeding.
• Non-serious adverse events (all adverse events that did not
fulfil the criteria for serious adverse events; ICH-GCP 1997).
Search methods for identification of studies
We will use a search strategy developed according to the Cochrane
Hepato-Biliary Group recommendations.
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (Gluud 2017), Cochrane Central Register of Con-
trolled Trials (CENTRAL; latest issue) in the Cochrane Library,
MEDLINE (1946 to the date of search; OvidSP), Embase (1974
to the date of search; OvidSP), and Science Citation Index Ex-
panded (1900 to the date of search,Web of Science) (Royle 2003)
using the preliminary strategies described in Appendix 1.
Searching other resources
We will scan the reference lists of relevant articles and proceedings
from meetings of the British Society for Gastroenterology (BSG),
the British Association for the Study of the Liver (BASL), the Eu-
ropean Association for the Study of the Liver (EASL), the United
European Gastroenterology Week (UEGW), the American Gas-
troenterological Association (AGA), and the American Associa-
tion for the Study of Liver Diseases (AASLD). We will write to
the principal authors of randomised clinical trials and pharma-
ceutical companies for additional information about completed
randomised clinical trials and for information about any ongoing
randomised clinical trials. We will also search online trial registries
such as ClinicalTrial.gov (clinicaltrials.gov/), European Medicines
Agency (EMA) (www.ema.europa.eu/ema/), World Health Orga-
nization (WHO) International Clinical Trial Registry Platform (
www.who.int/ictrp), and the US Food and Drug Administration
(FDA) (www.fda.gov) for ongoing or unpublished trials.
Data collection and analysis
The two review authors (LLG and MYM) will read the electronic
searches, perform additional manual searches, and list potentially
eligible randomised clinical trials; read the potentially eligible trial
reports; andparticipate in the final selectionof those to be included
in the analyses. The review authors will reach the final selection
through consensus. We will consult a Cochrane Hepato-Biliary
Group review arbiter should we be unable to reach consensus. For
randomised clinical trials reported in more than one publication,
we will select the paper reporting the longest duration of follow-
up as the primary reference.
Selection of studies
The two review authors (LLG and MYM) will participate in the
searches for eligible trials and data extraction, and they will list
the excluded trials with the reason for exclusion in the ’Charac-
teristics of excluded studies’ table. The review authors will resolve
disagreements through discussion, before conducting the analyses.
We will consult a Cochrane Hepato-Biliary Group review arbiter
should we be unable to reach consensus. We will identify and ex-
clude duplicates and collated multiple reports of the same study,
so that each study, rather than each report, is the unit of interest
in the review.
We will complete a PRISMA flow chart.
Data extraction and management
Two review authors (LLG and MYM) will independently collect
data and resolve contrary opinions through discussion. We will
use pilot tested data extraction sheets (developed, based on pilot
testing of four studies).Wewill consult aCochraneHepato-Biliary
Group review arbiter should we be unable to reach consensus. The
collected data will include information on:
• randomised clinical trials: design (cross-over or parallel),
settings (number of clinical sites; inclusion period), country of
origin;
• participants: size of varices, proportion of participants with
high-risk varices (based on the primary author’s definition),
mean age, proportion of men, aetiology of cirrhosis, proportion
of participants with Child-Pugh Class A/B/C;
• interventions: number of banding sessions, number of
bands used per session.
Wewill gather the primary and secondary outcome data, including
the criteria used in the definition of high- or low-risk varices,
methods, and definitions used to assess bleeding and bias control.
If we cannot find the relevant data in the published trial reports,
we will write to the primary investigators to ask for additional
information.
We will present the data in a ’Characteristics of included studies’
table.
Assessment of risk of bias in included studies
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We will assess bias control using the domains described in the
Cochrane Hepato-Biliary Group Module (Higgins 2011; Gluud
2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: not specified.
• High risk of bias: the sequence generation was not random.
We plan to include such studies for assessment of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: the outcome was mortality, which,
according to previous empirical evidence, is not likely to be
influenced by lack of blinding (Hróbjartsson 2001; Savovi
2012); or blinding of participants and key study personnel was
ensured, and it was unlikely that the blinding could have been
broken.
• Unclear risk of bias: insufficient information to permit
judgement of ’low risk’ or ’high risk.’
• High risk of bias: no blinding or incomplete blinding, and
the outcome was likely to have been influenced by lack of
blinding (non-mortality outcomes).
Blinding of outcome assessors
• Low risk of bias: the outcome was mortality, which,
according to previous empirical evidence, is not likely to be
influenced by lack of blinding (Hróbjartsson 2001; Savovi
2012); or blinding of outcome assessment was ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: insufficient information to permit
judgement of ’low risk’ or ’high risk.’
• High risk of bias: no blinding or inadequate blinding (e.g.
intravenous versus orally administered drugs) and the outcome
was likely to have been influenced by lack of blinding (non-
mortality outcomes).
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The investigators
used sufficient methods, such as intention-to-treat analyses with
multiple imputations or carry-forward analyses to handle missing
data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data induced bias on the results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically relevant
outcomes (mortality, hepatic encephalopathy, and serious adverse
events). If we had access to the original trial protocol, the
outcomes should be those called for in that protocol. If we
obtained information from a trial registry (such as
www.clinicaltrials.gov), we only used the information if the
investigators registered the trial before inclusion of the first
participant.
• Unclear risk of bias: predefined outcomes were not reported
fully.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support.
• Unclear risk of bias: no information on clinical trial support
or sponsorship was available.
• High risk of bias: the trial was sponsored by industry,
received support in the form of terlipressin or placebo, or
received any other type of support.
Other bias
• Low risk of bias: the trial appeared to be free of other biases
including: medicinal dosing problems or follow-up (as defined
under ’High risk of bias’ below).
• Unclear risk of bias: the trial may or may not have been free
of other domains that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias such as the administration of
inappropriate treatments being given to the controls (e.g. an
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inappropriate dose) or follow-up (e.g. the trial included different
follow-up schedules for participants in the allocation groups), or
premature discontinuation of the trial.
Overall bias assessment
• Low risk of bias: all domains were classified as low risk of
bias using the definitions described above.
• High risk of bias: one or more of the bias domains were
classified as unclear or high risk of bias.
Measures of treatment effect
We will use risk ratios (RR) for dichotomous outcomes and mean
differences (MD) for continuous outcomes, both with 95% con-
fidence intervals (CI). For statistically significant outcomes that
do not overlap the 95% CI, we will calculate the number needed
to treat for an additional beneficial outcome (NNTB) as 1/risk
difference (RD).
Unit of analysis issues
We do not expect to identify cross-over randomised clinical trials.
However, if we identify randomised clinical trials using a cross-
over design, we will include only the precross-over period in our
analyses.
Dealing with missing data
We will extract data on all randomised participants to allow inten-
tion-to-treat analyses. To evaluate the importance of missing data,
we will conduct a worst-case scenario analysis with inclusion of
missing outcomes as treatment failures. In addition, we will con-
duct an ’extreme’ worst-case scenario analysis in which we include
missing outcome data as treatment failures (intervention group)
or successes (control group).
Assessment of heterogeneity
We will express heterogeneity as I2 values using the following
thresholds: 0% to 40% (unimportant), 40% to 60% (moderate),
60% to 80% (substantial), and greater than 80% (considerable).
We will include this information in ’Summary of findings’ tables
(GRADEpro).
Assessment of reporting biases
For meta-analyses with at least 10 randomised clinical trials, we
will assess reporting biases through regression analyses and funnel
plots.
Data synthesis
We will perform the analyses in Review Manager 5 (RevMan
2014), STATA (Stata), and Trial Sequential Analysis (TSA 2011).
Meta-analysis
We will prepare separate meta-analyses of randomised clinical tri-
als evaluating the different intervention comparisons (i.e. we do
not plan to combine randomised clinical trials evaluating banding
ligation and randomised clinical trials evaluating sclerotherapy).
Wewill undertake both fixed-effect and random-effectsmeta-anal-
yses. The fixed-effect meta-analysis generates an estimate of a ’typ-
ical intervention effect’ from included randomised clinical trials
and calculates CIs with the assumption that the true intervention
effect is the same value in every randomised clinical trial. We will
report fixed-effectmodelmeta-analyses if we find evidence that the
observed differences among randomised clinical trials are due to
the play of chance. If we find ’unexplained’ heterogeneity, we will
incorporate heterogeneity into a random-effects model assuming
that the estimated effects are not identical, but follow a distribu-
tion. If we suspect that there may be an influence of small-study
effects on the results of our meta-analysis (e.g. heterogeneity, I2
greater than 0), we will compare the fixed-effect and random-ef-
fects estimates of the intervention effect. If the estimates are sim-
ilar, then we will assume that small-study effects have little effect
on the intervention effect estimate. If the two models are simi-
lar, we will report the result with the widest CIs. If the random-
effects estimate is more beneficial, we will consider whether it is
reasonable to conclude that the intervention is more effective in
the smaller randomised clinical trials or there is bias. If the larger
randomised clinical trials are conducted with a lower risk of bias
(or under more ’typical’ circumstances), then we will consider re-
porting the results of meta-analyses restricted to the larger, more
rigorous studies.
Trial Sequential Analysis
We will perform Trial Sequential Analyses (TSA 2011) and define
the required information size (also known as the diversity-adjusted
required information size) as the number of participants needed
to detect or reject an intervention effect based on the relative risk
reduction (RRR) and control group risk. The analyses will show
firm evidence if the Z-curves cross the monitoring boundaries
(also known as the trial sequential monitoring boundaries) before
reaching the required information sizes (TSA 2011). We will con-
struct futility boundaries to evaluate the uncertainty of obtaining
a chance negative finding and perform the analyses with alpha set
to 2.5%, beta 10%, and model-based diversity. Based on previous
evidence (Gluud 2007), we will set the RRR to the upper limit of
the 95% CI and use the control group event rate observed in the
meta-analysis. We will conduct the meta-analyses including only
randomised clinical trials with low risk of bias and including all
randomised clinical trials.
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Subgroup analysis and investigation of heterogeneity
We will conduct subgroup analyses to evaluate:
• randomised clinical trials using isosorbide mononitrate as a
concomitant intervention and randomised clinical trials not
using isosorbide mononitrate;
• people with high- or low-risk varices (using the original
investigators’ definitions);
• Child-Pugh Class A/B/C cirrhosis;
• randomised clinical trials with a ’low risk’ compared with
’high risk’ of bias in the overall assessment.
Sensitivity analysis
We will conduct a worst-case scenario analysis, and an ’extreme’
worst-case scenario analysis as described in Dealing with missing
data.
’Summary of findings’ tables
We will use the GRADE system to evaluate the quality of the
evidence for outcomes reported in the review (mortality, serious
adverse events, health-related quality of life, upper gastrointesti-
nal bleeding, variceal bleeding, non-serious adverse events) con-
sidering the within-study risk of bias (methodological quality),
indirectness of evidence (population, intervention, control, out-
comes), unexplained heterogeneity or inconsistency of results (in-
cluding problems with subgroup analyses); imprecision of effect
estimate (wideCIs and as evaluatedwith our Trial Sequential Anal-
yses), and risk of publication bias (GRADEpro). We will define
the certainty of the evidence as ’high’, ’moderate’, ’low,’ or ’very
low.’ These grades are defined as follows.
• High certainty: this research provides a very good
indication of the likely effect; the likelihood that the effect will
be substantially different is low.
• Moderate certainty: this research provides a good indication
of the likely effect; the likelihood that the effect will be
substantially different is moderate.
• Low certainty: this research provides some indication of the
likely effect; however, the likelihood that it will be substantially
different is high.
• Very low certainty: this research does not provide a reliable
indication of the likely effect; the likelihood that the effect will
be substantially different is very high.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search terms
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. (beta-blocker* OR ’adrenergic beta antagonist*’
OR propranolol OR atenolol OR nadolol OR
metoprolol OR bisoprolol OR carvedilol OR ter-
tatolol OR nipradilol OR penbutolol OR timolol
OR mepindolol) AND ’*esophageal varic*’
Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Li-
brary (Wiley)
Latest issue. #1 MeSH descriptor: [Adrenergic beta-Antago-
nists] explode all trees
#2 MeSH descriptor: [Propranolol] explode all
trees
#3 MeSH descriptor: [Atenolol] explode all trees
#4 MeSH descriptor: [Nadolol] explode all trees
#5MeSHdescriptor: [Metoprolol] explode all trees
#6 MeSH descriptor: [Bisoprolol] explode all trees
#7 MeSH descriptor: [Penbutolol] explode all trees
#8 MeSH descriptor: [Timolol] explode all trees
#9 beta-blocker* or ’adrenergic beta antagonist*’ or
propranolol or atenolol or nadolol or metoprolol or
bisoprolol or carvedilol or tertatolol or nipradilol
or penbutolol or timolol or mepindolol
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
or #9
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(Continued)
#11 MeSH descriptor: [Esophageal and Gastric
Varices] explode all trees
#12 *esophageal varic*
#13 #11 or #12
#14 #10 and #13
MEDLINE (OvidSP) 1946 to date of search. 1. exp Adrenergic beta-Antagonists/
2. exp Propranolol/
3. exp Atenolol/
4. exp Nadolol/
5. exp Metoprolol/
6. exp Bisoprolol/
7. exp Penbutolol/
8. exp Timolol/
9. (beta-blocker* or adrenergic beta antagonist* or
propranolol or atenolol or nadolol or metoprolol or
bisoprolol or carvedilol or tertatolol or nipradilol or
penbutolol or timolol or mepindolol).mp. [mp=ti-
tle, original title, abstract, name of substance word,
subject heading word, unique identifier]
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. exp “Esophageal and Gastric Varices”/
12. ((oesophageal or esophageal) and varic*).mp.
[mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
13. 11 or 12
14. 10 and 13
15. (random* or blind* or placebo* or meta-anal-
ysis).mp. [mp=title, original title, abstract, name
of substance word, subject heading word, unique
identifier]
16. 14 and 15
Embase (OvidSP) 1974 to date of search. 1. exp beta adrenergic receptor blocking agent/
2. exp PROPRANOLOL/
3. exp ATENOLOL/
4. exp NADOLOL/
5. exp METOPROLOL/
6. exp BISOPROLOL/
7. exp CARVEDILOL/
8. exp TERTATOLOL/
9. exp NIPRADILOL/
10. exp PENBUTOLOL/
11. exp TIMOLOL/
12. exp MEPINDOLOL/
13. (beta-blocker* or adrenergic beta antagonist*
or propranolol or atenolol or nadolol or meto-
prolol or bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or mepindolol)
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(Continued)
.mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device man-
ufacturer, drug manufacturer]
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
or 11 or 12 or 13
15. exp esophagus varices/
16. ((oesophageal or esophageal) and varic*).
mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device man-
ufacturer, drug manufacturer]
17. 15 or 16
18. 14 and 17
19. (random* or blind* or placebo* or meta-analy-
sis).mp. [mp=title, abstract, subject headings, head-
ing word, drug trade name, original title, device
manufacturer, drug manufacturer]
20. 18 and 19
Science Citation Index Expanded (Web of
Science)
1900 to date of search. # 4 #3 AND #2 AND #1
# 3 TS=(random* or blind* or placebo* or meta-
analysis)
# 2 TS=((oesophageal or esophageal) and varic*)
# 1 TS=(beta-blocker* or adrenergic beta antago-
nist* or propranolol or atenolol or nadolol or meto-
prolol or bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or mepindolol)
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